BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Art Pappas will moderate and lead a discussion entitled "Are we Heading into a Pharmaceutical and Biotechnology Market of Orphan and Narrow Indications" at the 2012 BIO International Convention on June 19th in Boston, MA.
News | 02. 29. 2012
Art Pappas will moderate and lead a discussion entitled "Are we Heading into a Pharmaceutical and Biotechnology Market of Orphan and Narrow Indications" at the 2012 BIO International Convention on June 19th in Boston, MA.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.